↓ Skip to main content

Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap

Overview of attention for article published in Journal for Immunotherapy of Cancer, July 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)

Mentioned by

twitter
8 tweeters
patent
1 patent
googleplus
1 Google+ user

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap
Published in
Journal for Immunotherapy of Cancer, July 2017
DOI 10.1186/s40425-017-0265-y
Pubmed ID
Authors

Frederick L. Locke, Claudio Anasetti

Abstract

Recent single institution clinical trial successes with anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for B cell malignancies attracted significant attention from industry. Our center sought to rapidly and safely bring industry sponsored pivotal trials to our patients and to prepare for additional cell therapy trials in solid and liquid tumors from both industry and our own investigators. We implemented a collaborative cross departmental program to provide clinical care and trial coordination for immune cell therapies. The Moffitt Immune Cell Therapy (ICE-T) program oversees and administers not only CAR T cell therapy for hematologic malignancies, but TIL and TCR therapy for solid tumor patients. Disease specific experts maintain oversight as principal investigators of these key trials yet the coordination and clinical care is centralized to leverage the expertise and infrastructure of our already robust Blood and Marrow Transplantation program.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 18%
Student > Master 3 18%
Researcher 2 12%
Other 1 6%
Student > Bachelor 1 6%
Other 2 12%
Unknown 5 29%
Readers by discipline Count As %
Medicine and Dentistry 5 29%
Pharmacology, Toxicology and Pharmaceutical Science 2 12%
Agricultural and Biological Sciences 2 12%
Materials Science 1 6%
Engineering 1 6%
Other 0 0%
Unknown 6 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2019.
All research outputs
#2,639,918
of 16,414,025 outputs
Outputs from Journal for Immunotherapy of Cancer
#418
of 1,552 outputs
Outputs of similar age
#57,754
of 269,470 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 16,414,025 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,552 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 269,470 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them